Citation: “Company Showcase: PCI Pharma Services”. ONdrugDelivery, Issue 152 (Oct 2023), pp 116–118.
PCI Pharma Services showcases its portfolio of drug delivery-relevant solutions, including: sterile fill-finish and lyophilisation; drug-device combination product design and development; packaging for injectables; and Speedsolutions™ supply chain simplification, and also highlights plans for the expansion both of its global sterile fill-finish and lyophilisation manufacturing capabilities and its commercial advanced drug delivery packaging service offering for injectables.
ADVANCED DRUG DELIVERY SOLUTIONS
Seeking advanced drug delivery for targeted and controlled release of novel molecules, PCI Pharma Services‘ integrated drug manufacturing and packaging solutions support biopharma companies in optimising dosing and providing convenient, easy-to-use, patient-centric therapies to patients.
“PCI has the scalability to handle the dynamic volumes of biopharmaceutical therapies, whether large or small, from niche personalised medicines to large-volume treatments.”
STERILE FILL-FINISH AND LYOPHILISATION
PCI’s global manufacturing capabilities in complex sterile formulations and lyophilisation cover a broad range of next-generation injectable technologies, including nanoparticles, mRNA, monoclonal antibodies, proteins, oligonucleotides and other biologics across multiple delivery formats, from vials and prefilled syringes to cartridges for autoinjectors (Figure 1). PCI provides integrated large- and small-molecule solutions for clinical and commercial projects and, with over 20 years in the sterile fill-finish and lyophilisation manufacturing space, the company is dedicated to its partners’ success in bringing life-changing therapies to patients.
DRUG-DEVICE COMBINATION PRODUCTS
Driven by innovation and patient centricity, PCI’s design and development expertise, combined with its device assembly and advanced packaging capabilities, offers flexible solutions for a diverse portfolio of conventional and specialty injectable drug delivery devices (Figure 2). PCI has the scalability to handle the dynamic volumes of biopharmaceutical therapies, whether large or small, from niche personalised medicines to large-volume treatments.
Tailored to its partners’ unique design, development and manufacturing needs, PCI offers a complete range of capabilities, services and expertise:
- Expert design process focused on human-factors engineering and technical functionality
- Optimising designs for manufacturability, scalability and automation
- Fully end-to-end drug-device combination packaging including:
– Prefilled syringe assembly
– Pen injector, autoinjector and on-body injector final assembly
– Safety syringe assembly and precision labelling
– Integrated top-load cartoning
– In-process testing and final release
– Cold-chain storage.
“PCI facilitates rapid prototype design to support patient and physician focus groups that provide vital insight into patient usability and acceptability.”
INJECTABLE PACKAGING SERVICES – CLINICAL THROUGH COMMERCIAL
With true customer focus and flexibility at the core of its pharmaceutical packaging service offering, PCI is able to adapt to the unique requirements of each global market, from concept to commercialisation. PCI is the partner of choice in providing scalable packaging services, supporting niche orphan drugs through to large-scale biopharmaceuticals with tailored injectable packaging solutions including:
- Labelling of vials, ampoules, pens, prefilled syringes, autoinjectors and on-body injectors
- Tyvek blistering for parenterals
- Drug-device combination product assembly
- Kitting and protective packaging
- Overwrapping and pouching
- Cold chain packaging and labelling (2–8°C, -20°C, -40°C, -80°C, -196°C).
Harnessing decades of drug product development and commercialisation experience, PCI’s integrated speed solutions simplify supply chains from the earliest stages of development through to approval, launch and beyond. Speed solutions, such as packaging design and artwork services, provide innovative, value-added services for its clients. PCI’s dedicated team of in-house design specialists deliver insightful packaging design and practical knowledge to deliver differentiated and cost-effective packaging solutions. Using three-dimensional modelling, PCI facilitates rapid prototype design to support patient and physician focus groups that provide vital insight into patient usability and acceptability, as well as supporting regulatory filings, expediting responses and enabling true speed to market.
Meeting the growing needs of its clients for their life-changing biologic drug products, PCI continues to invest in both its manufacturing and packaging capacities and capabilities. Over the next 12 to 18 months, PCI has committed to invest over US$250 million (£202 million) to expand its global sterile fill-finish and lyophilisation manufacturing capabilities together with its clinical and commercial advanced drug delivery packaging service offering for injectables.
These investments reflect the outlook and the market demand PCI envisages for injectable drug products. As a leading global CDMO, PCI not only wants to meet growing demand for scalable biologic manufacturing and advanced drug delivery packaging but, through innovative value-add solutions, the company aims to exceed customer expectations, delivering flexibility and excellence in all that it does to accelerate the development and commercialisation of life-changing therapies.
Find out more about solutions from PCI Pharma Services here: pci.com.
Previous articleINTERVIEW: DOUG BRYANS, BRYLLAN & JOHN MERHIGE, CREDENCE
Next articleAUTOMATING ASSEMBLY TO EXPEDITE TIME-TO-MARKET